In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DNA Sciences Inc.

Division of Allergan PLC
www.dna.com

Latest From DNA Sciences Inc.

Deal Statistics Quarterly, Q2 2003

In Vivo presents another installment of our quarterly reivew of dealmaking--in this case April-June 2003. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
BioPharmaceutical Medical Device

The Best of Three Worlds

Celera Diagnostics, a 50/50 JV between Applera Corp.'s two divisions, Applied Biosystems and Celera Genomics, is using the discovery, assay development, and systems expertise of its founders to help it commercialize reagent and software-based standardized molecular diagnostic tests. But Applera didn't step up to the plate until after it obtained an expanded license to PCR from Roche, giving it freedom to operate in the diagnostics arena, and convinced Kathy Ordoñez, president of Roche Molecular Systems, to join Applera and head the diagnostics program. Celera Diagnostics believes it will distinguish itself from other genomics-based companies pursuing diagnostics -- as well as from the traditional diagnostics players - by being able to efficiently discover new diagnostic markers by performing association studies to confirm the link between SNP sets and disease. Celera Diagnostics could also serve as an "earliest access" customer that contributes to and drives a new molecular diagnostics platform strategy for Applied Bio.
Medical Device North America

Why Don't Big Pharmas Buy Pharmacogenomics?

Pharmacogenomics has disappointed advocates who saw the opportunity to apply a discovery tool to the near-term goal of increasing approval chances and marketability for late-stage and marketed compounds. In return, they hoped to take a percentage of the highest-cost segment of the pharmaceutical budget. But Big Pharma is by and large not using pharmacogenomics for late-stage and marketed compounds: senior executives don't believe there's enough evidence it works and are afraid of limiting the marketability of the products by segmenting broad target populations into niches. Some also worry about uncovering potential side-effects that non-pharmacogenomic trials wouldn't reveal. Nonetheless, pharmacogenomics has made it to Big Pharma: most companies, for example, are banking samples from clinical trials to be pharmacogenomically tested retrospectively, thereby informing future trials. Not that this means the pharmacogenomics specialists will be able to sign high-value deals with the commercial side of drug companies, who believe that pharmacogenomic analysis is available from a number of sources, including internal ones, and feel they own the key assets for creating meaningful programs: compounds and patient samples. Instead, pharmacogenomics will find its place first as a discovery technology, integrated with other methods for finding, validating and prioritizing targets. That means that to succeed selling pharmacogenomics, biotechs will have to combine their pharmacogenomic assets with other discovery technologies, perhaps through mergers. An alternative: use their technologies to find drug products that they can themselves develop, perhaps later out-licensing them.
BioPharmaceutical Strategy

Deal Statistics Quarterly, Q3 2001

In Vivo presents another installment of our quarterly review of dealmaking--in this case July 2001-September 2001. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
BioPharmaceutical Medical Device
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register